Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Embl Ventures Portfolio Company, Viratherapeutics Acquired By Boehringer Ingelheim In EUR 210
LPNEWS

Embl Ventures Portfolio Company, Viratherapeutics Acquired By Boehringer Ingelheim In EUR 210

by prnewswire.co.uk posted 5days ago 12 views
HEIDELBERG, Germany, September 13, 2018 /PRNewswire/ -- ViraTherapeutics sale marks third exit from EMBL Ventures' current fund ETF II EMBL Ventures, a leading early stage European life science venture capital firm, today announces that Boehringer Ingelheim has exercised its...

In this article